Shield Therapeutics plc (LON:STX – Get Free Report)’s share price crossed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of GBX 6.18 and traded as low as GBX 5.60. Shield Therapeutics shares last traded at GBX 5.71, with a volume of 3,651,834 shares.
Shield Therapeutics Price Performance
The business has a 50 day simple moving average of GBX 6.18 and a two-hundred day simple moving average of GBX 8.14. The firm has a market capitalization of £63.83 million, a P/E ratio of -2.98 and a beta of 1.76. The company has a debt-to-equity ratio of -199.87, a quick ratio of 2.16 and a current ratio of 0.90.
Shield Therapeutics Company Profile
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.
Further Reading
- Five stocks we like better than Shield Therapeutics
- AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next
- Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now
- Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There?
- Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
